Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue JVIR: Journal of Vascular and Interventional Radiology Année : 2015

Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.

Résumé

Synergy between yttrium-90 ((90)Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI \textless 1 denoting synergy and CI \textgreater 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with (90)Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with (90)Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with (90)Y radioembolization for treatment of liver cancer.

Domaines

Médicaments Cancer
Fichier principal
Vignette du fichier
Gemcitabine and Oxaliplatin but Not Sorafenib or Paclitaxel_accepted.pdf (527.84 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-01237102 , version 1 (31-05-2016)

Identifiants

Citer

Julien Edeline, Cédric Coulouarn, Laurence Crouzet, Marc Pracht, Nicolas Lepareur, et al.. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.. JVIR: Journal of Vascular and Interventional Radiology, 2015, 26 (12), pp.1874--1878.e2. ⟨10.1016/j.jvir.2015.06.032⟩. ⟨hal-01237102⟩
347 Consultations
409 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More